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OBJECTIVES This study was designed to test whether intravenous (IV) amiodarone would prevent atrial
fibrillation and decrease hospital stay after open heart surgery.
BACKGROUND Atrial fibrillation commonly occurs after open heart procedures and is thought to be a
significant determinant for prolongation of hospitalization. Oral amiodarone given preoper-
atively appears to reduce the incidence of atrial fibrillation. This study was designed to test
whether the more rapid-acting IV formulation of amiodarone given postoperatively would
reduce the incidence of atrial fibrillation.
METHODS Three hundred patients undergoing standard open heart surgery were randomized in a
double-blind fashion to IV amiodarone (1 g/day for 2 days) versus placebo immediately after
open heart surgery. The primary end points of the trial were incidence of atrial fibrillation and
length of hospital stay. Baseline clinical variables and mortality and morbidity data were
collected.
RESULTS Atrial fibrillation occurred in 67/142 (47%) patients on placebo versus 56/158 (35%) on
amiodarone (p 5 0.01). Length of hospital stay for the placebo group was 8.2 6 6.2 days, and
7.6 6 5.9 days for the amiodarone group (p 5 0.34). No differences were noted in baseline
variables, morbidity or mortality.
CONCLUSIONS Low-dose IV amiodarone was safe and effective in reducing the incidence of atrial fibrillation
after heart surgery, but did not significantly alter length of hospital stay. (J Am Coll Cardiol
1999;34:343–7) © 1999 by the American College of Cardiology
Atrial fibrillation frequently occurs after open heart surgery,
with estimates ranging to 50% (1–7). Matthew et al. (2)
recently reported the results from one of the largest studies
on postoperative atrial fibrillation. The MultiCenter Study
of Perioperative Ischemia demonstrated a frequency of atrial
fibrillation following coronary bypass grafting of 27%.
Multiple risk factors were identified including age, heart
failure and some surgical practices. Moreover, hospital
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length of stay was significantly prolonged in those patients
who experienced atrial fibrillation. Other investigators have
reported similar frequencies, risk factors and prolongation of
hospitalizations (8–15).
A number of strategies involving pharmacologic prophy-
laxis have been used to prevent atrial fibrillation after bypass
surgery (16–27). A recent report suggests that large oral
doses of amiodarone may be effective for reducing both the
incidence of postcoronary bypass atrial fibrillation and
length of hospital stay (28). Daoud et al. (28) utilized several
days of preoperative oral amiodarone to load the patients
with the drug. Alternatively, low-dose intravenous (IV)
amiodarone has been demonstrated to treat refractory ven-
tricular tachycardia in hours as opposed to days for the oral
preparation (29,30). Because the IV formulation appears to
act so rapidly, we initiated the ARCH study (Amiodarone
Reduction in Coronary Heart study) to examine whether IV
postoperative amiodarone will prevent atrial fibrillation and
reduce length of hospital stay.
The ARCH study was designed to test the hypotheses
that low-dose IV amiodarone, given postoperatively, would
reduce the frequency of atrial fibrillation and the length of
hospital stay. The ARCH study was conducted as a ran-
domized double-blind trial of IV amiodarone versus placebo
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at a single surgical center in 300 patients with no history of
atrial fibrillation undergoing standard open heart procedures.
METHODS
Patient population. From September 9, 1996, to August
12, 1997, patients undergoing standard open heart surgery
with no evidence of preoperative atrial fibrillation were
screened for participation in this study, which was reviewed
and approved by the St. Joseph Medical Center Institutional
Review Board. All patients signed informed consent. Three
hundred patients were enrolled. All patients underwent
standard open heart procedures via midline sternotomy. We
excluded patients undergoing other methods of cardiac
surgery, including lateral thoracotomy, “mid-cab,” or vari-
ous thoracoscopy approaches. Patients were excluded if they
had any history of atrial fibrillation or were taking class I or
class III antiarrhythmic drugs. Patients were included if they
were taking digoxin, beta-blockers or calcium channel
blockers for reasons other than any cardiac arrhythmia. As
intended, drug was not infused in randomized patients if
they arrived in the surgical intensive care unit in atrial
fibrillation, had an aortic counterpulsation balloon in place
or the first two cardiac indexes (determined by thermodilu-
tion technique at least 4 h apart) were less than 2.0
liter/min/m2. These randomized but not infused patients
were included in the analysis as intention to treat.
Randomization and drug administration. Patients were
randomly assigned in a double-blind fashion to receive
either IV amiodarone or placebo infused through a central
venous catheter. A 1:1 treatment allocation scheme was
used in this study. The amiodarone was infused at a rate of
1 g over 24 h, given for a total of 48 h (2 g total). No loading
dose was given. The drug infusion was started within 3 h of
entering the surgical intensive care unit. The only hemody-
namic parameter for terminating infusion was systolic blood
pressure consistently ,80 mm Hg. Because all patients
received temporary atrial and ventricular pacing wires,
bradycardia was not a parameter for study termination.
Study end points. The primary end points of this study
were the development of postoperative atrial fibrillation,
detected via continuous ambulatory monitoring, and hospi-
tal length of stay. Atrial fibrillation was defined as any
episode of atrial fibrillation requiring any treatment. Treat-
ment for atrial fibrillation was not controlled. Patients were
all followed up to one month after discharge. At the one
month visit, rhythm analysis was performed. The investi-
gators did not have access to the data until the trial was
complete and analysis had been concluded. The data re-
ported are based on 100% level of completeness for length of
hospital stay and incidence of atrial fibrillation.
Statistical analysis. Data were analyzed using the
intention-to-treat principle. Continuous data are summa-
rized as means 6 SD. Discrete variables were compared
between treatment groups by the chi-square test, and
continuous variables were compared by means of the Stu-
dent t test. Kaplan-Meier analysis with the log-rank test was
used to compare the probability of postoperative atrial
fibrillation by treatment group.
RESULTS
A total of 300 patients were randomized in this study. Over
28 baseline characteristics were prospectively collected.
There were no differences in the treatment groups. Repre-
sentative baseline characteristics, displayed in Table 1,
reflect the similarity in the two groups. Specifically, age,
indexes of ventricular function and incidence of co-morbid
illness were identical in the two groups. It should be noted
that about one-third of the population was older than 70
years, and a significant proportion had left ventricular
dysfunction. Approximately 50% of both populations were
taking some formulation of beta-adrenergic blocking agent
before surgery (Table 1). By the time of discharge, 18.1%
(25 of 142) of the control group and 11.4% (17 of 158) of
the amiodarone-treated group had beta-blockers discontin-
ued (p 5 0.18). Operative characteristics are displayed in
Table 2. There were no differences in the operative inter-
ventions or techniques between the two treatment groups.
One patient in the placebo group (listed as “other”) had an
atrial septal defect repair. In this population, there were no
differences in location of grafts or vessels bypassed.
Study drug was not infused in 14 (5%) of the 300
randomized patients: 6 patients in the placebo group and 8
in the amiodarone group received no infusion because of
immediate postoperative hemodynamic instability. The
study drug was terminated prematurely in seven (4.4%) of
Table 1. Baseline Characteristics of the Patients
Placebo
(n 5 142)
Amiodarone
(n 5 158)
Age (yrs) 63.9 63.3
Age $70 (%) 33.8 32.9
Male gender (%) 76.8 74.0
Hypertension (%) 76.8 69.6
Diabetes (%) 30.3 29.7
Current smoker (%) 12.0 16.4
Prior myocardial infarction 37.3 34.8
History of congestive heart
failure (%)
12.0 8.9
Chronic obstructive pulmonary
disease (%)
9.2 5.1
Peripheral vascular disease (%) 18.3 19.6
Prior stroke (%) 7.7 6.3
Preoperative use of beta-
blockers (%)
50.7 52.5
Preoperative use of digitalis (%) 5.3 4.7
Preoperative use of calcium
channel blockers (%)
45.8 41.1
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the patients assigned to amiodarone and in two (1.4%)
patients assigned to placebo (p 5 0.12) (Table 3). All
patients were included in the analysis as intention to treat.
Because all patients had temporary epicardial atrial and
ventricular pacing wires placed, bradycardia was not an
indication for infusion termination. Nonetheless, two pa-
tients had failure of capture of the atrial leads during mild
bradycardia, for which the infusion was terminated.
Atrial fibrillation developed in 67 of 142 patients assigned
to placebo (47% incidence) and in 56 of 158 (35%) patients
assigned to amiodarone (p 5 0.01), representing a 26%
relative risk reduction. The percentages of patients free of
atrial fibrillation during hospitalization by treatment group
are shown in Figure 1, and confirm a significant reduction in
atrial fibrillation in the amiodarone group. Analysis of the
Kaplan-Meier curve demonstrates that the drug effect ap-
pears to occur in the first few days of treatment. The first
episode of atrial fibrillation occurred on postoperative day
2.9 6 1.2 in the group receiving amiodarone and on day
2.3 6 1.3 in the placebo group (p , 0.01). The mean
ventricular response rate during at least 30 s of the first
episode of atrial fibrillation was 135.5 6 31.3 beats/min in
the placebo group and 128.8 6 28.7 beats/min in the
amiodarone-treated group (p 5 0.26). Average hospital
charges for the placebo group were $18,889; for the amio-
darone group (p 5 0.18), hospital charges averaged
$16,871.
The length of hospital stay did not statistically differ
between treatment groups: 7.6 6 5.9 days for the amioda-
rone group versus 8.2 6 6.2 days for the placebo group (p 5
0.34). As in other studies, atrial fibrillation was associated
with a prolonged length of hospital stay regardless of
treatment assignment. Patients who experienced atrial fi-
brillation had a length of stay of 9.0 6 5.1 days; the length
of hospital stay in those patients free of atrial fibrillation was
7.1 6 6.6 days (p , 0.01).
Nonfatal postoperative complications occurred in four
(2.5%) patients who received amiodarone and in seven
(4.9%) patients receiving placebo (p 5 0.27). No deaths
(0%) occurred in the amiodarone group, whereas two deaths
(1.4%) occurred among patients in the placebo group (p 5
0.13) (Table 4).
Table 2. Operative Characteristics
Placebo
(n 5 142)
Amiodarone
(n 5 158)
Type of cardiac procedure (%)
Coronary bypass only 83.1 86.1
Coronary bypass & valvular 12.0 8.9
Valvular only 4.2 5.1
Other (atrial septal defect) 0.7 0.0
No. of grafts 4.0 6 1.6 4.1 6 1.5
Bypass time (min) 100.6 6 37.4 95.0 6 32.7
Left ventricular ejection
fraction
0.46 6 0.26 0.43 6 0.28
Table 3. Incomplete Drug Infusion
Patient No.
Total Drug
Infused
Reason for
Termination
Amiodarone group
1 483 mg Bradycardia, pacemaker
failure
2 189 mg Ventricular tachycardia
3 378 mg Central line bleeding
4 588 mg Central line clot
5 378 mg Stroke
6 546 mg Hypotension
7 546 mg Bradycardia, pacemaker
failure
Placebo group
1 — Atrial flutter
2 — Cardiac arrest
Figure 1. Displayed is the freedom-from-atrial fibrillation in the
days after open heart surgery. Both populations have complete
follow-up to 30 days. (Solid diamond 5 placebo group; open
square 5 amiodarone group.)
Table 4. Incidence of Major Morbidity and Mortality
Placebo
(n 5 142)
Amiodarone
(n 5 158)
Major morbidity
Acute renal failure (%) 1.4 0.6
Cerebrovascular accident (%) 1.4 1.3
Pneumonia (%) 0.7 0.6
Ventricular fibrillation (%) 1.4 0.0
Total (%) 4.9 2.5
Mortality
Cardiac arrest (%) 0.7 0.0
Cerebral hemorrhage (%) 0.7 0.0
Total (%) 1.4 0.0
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At the four- to six-week follow-up, 236 patients were in
sinus rhythm, 5 were in atrial fibrillation and 59 had no
electrocardiographic documentation of rhythm.
DISCUSSION
Atrial fibrillation after open heart surgery. Atrial fibril-
lation remains one of the most frequent complications of
coronary bypass surgery. Matthew et al. (2) reported the
outcomes of over 2,000 patients examined in the Multi-
center Study of Perioperative Ischemia. In that multicenter
database, the incidence of atrial fibrillation was 27%. Aranki
et al. (1) reported the results on over 500 patients from a
single center. In that series the incidence was 33%. Both of
these large series and several smaller ones suggest the
incidence of atrial fibrillation may range from 25% to 50%
(1,2,28).
Both Matthew and Aranki also provided strong evidence
that atrial fibrillation significantly prolonged hospitalization
and increased resource utilization (1,2). In the Perioperative
Ischemia study, both prolonged hospitalization (two days)
and extra time in the intensive care unit (13 h) were noted.
Aranki (1) demonstrated that atrial fibrillation was associ-
ated with an extra 4.9 days of hospitalization with estimated
additional charges of $10,055.
Amiodarone and atrial fibrillation after open heart sur-
gery. The ARCH study is the largest randomized trial of
IV amiodarone given as prophylaxis for postoperative atrial
fibrillation. The primary finding of this study is that low
dose IV amiodarone decreases the incidence of atrial fibril-
lation after open heart surgery by 26%. The protocol was
designed specifically to analyze the effects of the IV formu-
lation of amiodarone given only in the immediate postop-
erative period. Unlike the oral compound, which has an
onset of action of at least several days, IV amiodarone
appears to act within a few hours as judged by the treatment
of refractory ventricular tachycardia (29,30). We speculated
that the rapid onset of the IV formulation of amiodarone
could provide enough drug to prevent atrial fibrillation in
the days immediately postbypass when atrial fibrillation was
manifest. Because many of the patients in this series were
identified as urgent candidates for bypass and were not seen
in the outpatient clinic before surgery, the concept of
administering drug only in the immediate postoperative
period was both attractive and practical.
Amiodarone has been used before to prevent atrial
fibrillation in small series, often combining the oral and IV
formulation. Butler et al. (31) administered 15 mg/kg of
amiodarone immediately after releasing the aortic cross
clamp followed by 600 mg/day for three days. Eight percent
of the amiodarone-treated group had “clinically significant”
supraventricular arrhythmias as compared with 20% in the
placebo control group. Hohnloser and colleagues (32) ad-
ministered a loading IV bolus of 300 mg of amiodarone
postoperatively followed by 1200 mg/day for two days and
900 mg/day for two days. Eight of 38 control patients (21%)
experienced atrial fibrillation while only 2 of 39 (5%)
patients treated with amiodarone had atrial fibrillation. The
ARCH study demonstrated a similar risk reduction. More
recently, Daoud (28) identified patients preoperatively and
gave 600 mg orally per day for seven days before surgery
followed by 200 mg/day until discharge. In the control
group, 32 of 64 (50%) experienced atrial fibrillation,
whereas 16 of 64 (25%) treated with amiodarone had atrial
fibrillation. The degree of benefit appears to be greatest in
the Daoud study, possibly because of the large preoperative
dose, 4.8 g. All of these studies, including the ARCH study,
have shown significant reduction in the incidence of atrial
fibrillation after open heart surgery with prophylactic ami-
odarone.
Atrial fibrillation and length of hospital stay. Several
studies have examined whether atrial fibrillation is an
important risk factor for prolonging hospitalization. In the
large Multicenter Study of Perioperative Ischemia, 2,417
patients were studied (2). Patients with atrial fibrillation had
a 2.0-day longer hospitalization than did those without
atrial fibrillation. Similarly, Aranki (1) reported a single-
center series of 570 patients. The length of stay for patients
with atrial fibrillation was 15 days, compared with 9 days in
those without atrial fibrillation (1). Both studies strongly
supported the hypothesis that atrial fibrillation was an
important independent variable in length of hospital stay.
Daoud was the first to demonstrate that amiodarone treat-
ment resulted in a shortening of hospitalization: 7.9 days for
the control and 6.5 days for the treated group (28). Daoud
and co-workers proposed that the decrease in hospitaliza-
tion reduced costs from approximately $26,000 in the
control group to $18,000 in the treated group. The ARCH
study showed a nonsignificant but similar trend in reducing
hospitalization, 8.2 days for controls and 7.5 days for the
treatment group.
Complications of therapy. None of the prospective trials
of prophylactic amiodarone has shown any significant mor-
tality or morbidity from the drug (28,31,32). Previous trials
had relatively small numbers and may not have been
powered to detect what is probably a small drug risk. In the
ARCH study, which is the largest to date, we found no
evidence of morbidity or mortality secondary to therapy.
Certainly, the short-term exposure to rather modest total
doses of amiodarone may be the most important factor in
reducing drug risk.
Study limitations. The ARCH study was specifically de-
signed to test the effect of low doses of IV amiodarone in
preventing atrial fibrillation when given postoperatively. It
should be noted that atrial fibrillation tended to occur at day
3 in the treated group, after the termination of the infusion.
Certainly, a strategy could have been used to give higher
total doses, either by increases in concentration or length of
infusion, or addition of oral compound. Given the results of
the Daoud report (28), it is possible that higher total doses
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might have a more pronounced effect. The ARCH study
did not demonstrate a significant decrease in hospitaliza-
tion, one of the primary end points. The study was powered
to detect a 20% reduction in atrial fibrillation, but it may not
have been sufficiently powered to detect differences in
hospitalization because of the large variances involved.
Conclusions. Intravenous amiodarone given in the imme-
diate postoperative period is safe and effective in reducing
the incidence of atrial fibrillation. The degree of risk
reduction was not sufficient to produce a significant decrease
in hospitalization.
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